The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index.
Mechanisms underlying metabolic disturbances associated with psychosis and antipsychotic drug treatment
Abstract
The increase in cardiovascular disease and reduced life expectancy in schizophrenia likely relate to an increased prevalence of metabolic disturbances. Such metabolic risk factors in schizophrenia may result from both symptom-related effects and aetiological factors. However, a major contributory factor is that of treatment with antipsychotic drugs. These drugs differ in effects on body weight; the underlying mechanisms are not fully understood and may vary between drugs, but may include actions at receptors associated with the hypothalamic control of food intake. Evidence supports 5-hydroxytryptamine receptor 2C and dopamine D2 receptor antagonism as well as antagonism at histamine H1 and muscarinic M3 receptors. These M3 receptors may also mediate the effects of some drugs on glucose regulation. Several antipsychotics showing little propensity for weight gain, such as aripiprazole, have protective pharmacological mechanisms, rather than just the absence of a hyperphagic effect. In addition to drug differences, there is large individual variation in antipsychotic drug-induced weight gain. This pharmacogenetic association reflects genetic variation in several drug targets, including the 5-hydroxytryptamine receptor 2C, as well as genes involved in obesity and metabolic disturbances. Thus predictive genetic testing for drug-induced weight gain would represents a first step towards personalised medicine addressing this severe and problematic iatrogenic disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Weight gain is a well-established side effect of all anti-psychotics, especially the second-generation anti-psychotics such as clozapine and olanzapine, by antagonizing 5-hydroxy tryptamine receptor, dopamine receptor, and histamine and muscarinic receptors [37].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [37]
Citations
Cites
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382 · cited 1×
“Antipsychotic drug effects on body weight and the control of food intake From the initial meta-analysis of Allison et al. (1999) to other direct comparison meta-analyses (e.g. Rummel-Kluge et al., 2010) and the multiple comparison meta-analysis from Leucht et al. (2013), evidence from randomised…”
MethodTiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Second-Generation (Atypical) Antipsychotics and Metabolic Effects: A Comprehensive Literature Review
Newcomer, J. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519001-00001 · Cited by 1,340 · cited 2×
“Others have demonstrated antipsychotic-associated insulin resistance (Henderson et al., 2005) with the greatest effects on glucose elevation with olanzapine and clozapine (Newcomer, 2005; Rummel-Kluge et al., 2010).”
BackgroundAdiponectin Levels and Risk of Type 2 Diabetes: A Systematic Review and Meta-analysis
Li, S., Shin, H. J., Ding, E. L., & van Dam, R. M. (2009) · JAMA · doi:10.1001/jama.2009.976 · Cited by 991 · cited 3×
“Thus, in addition to receptor targets of antipsychotics, these findings implicate genes involved in the hypothalamic control of food intake and body weight and (e.g. MC4R) and other genetic risk factors for obesity and metabolic disturbances (e.g. INSIG2, BDNF).”
ResultDe Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.005 · Cited by 951
Leptin Receptor Signaling in Midbrain Dopamine Neurons Regulates Feeding
Hommel, J. D., Trinko, R., Sears, R. M., Georgescu, D., Liu, Z.-W., Gao, X.-B., Thurmon, J. J., Marinelli, M., & DiLeone, R. J. (2006) · Neuron · doi:10.1016/j.neuron.2006.08.023 · Cited by 902 · cited 1×
“…process, more recently it has been shown that the mesolimbic dopamine pathway, implicated in reward mechanisms, locomotor function and particularly the antipsychotic response, can also mediate leptin’s effects on food intake through leptin receptors on these dopaminergic neurons (Hommel, 2006).”
BackgroundKroeze, W. K., Hufeisen, S. J., Popadak, B. A., Renock, S. M., Steinberg, S., Ernsberger, P., Jayathilake, K., Meltzer, H. Y., & Roth, B. L. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300027 · Cited by 801 · cited 1×
“There have been attempts to identify receptor mechanisms of weight gain by correlation between the affinities of antipsychotic drugs at various candidate neurotransmitter receptors and their weight-gain liabilities in the clinic (Kroeze et al., 2003, MatsuiSakata et al., 2005).”
BackgroundRummel-Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C. A., Kissling, W., Davis, J. M., & Leucht, S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.07.012 · Cited by 675 · cited 3×
“Others have demonstrated antipsychotic-associated insulin resistance (Henderson et al., 2005) with the greatest effects on glucose elevation with olanzapine and clozapine (Newcomer, 2005; Rummel-Kluge et al., 2010).”
BackgroundMethodAbnormalities in Glucose Regulation During Antipsychotic Treatment of Schizophrenia
Newcomer, J. W., Haupt, D. W., Fucetola, R., Melson, A. K., Schweiger, J. A., Cooper, B. P., & Selke, G. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.4.337 · Cited by 520 · cited 1×
“Certainly some antipsychotic drugs, primarily clozapine and olanzapine, appear to have effects on glucose regulation independent of adiposity in people without diabetes (Newcomer et al., 2002).”
Background
Research works printed but not linked: 2
- 10.1037/0735-7044.105.2.272 · DOI
- Reynolds GP, 2016, Poster presented at British Association for Psychopharmacology Summer Meeting
Cited by
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Mazereel, V., Detraux, J., Vancampfort, D., van Winkel, R., & De Hert, M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.573479 · Cited by 205
“Clozapine and olanzapine, having the highest weight gain liability, also have a very strong binding affinity to both 5-HT2C and H1 receptors (21).”
BackgroundHiggins‐Chen, A., Boks, M. P., Vinkers, C. H., Kahn, R. S., & Levine, M. E. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.01.025 · Cited by 110
Skonieczna‐Żydecka, K., Łoniewski, I., Misera, A., Stachowska, E., Maciejewska, D., Marlicz, W. M., & Galling, B. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5102-6 · Cited by 106
“Notably, SGAs have also been found to affect food intake habits (Reynolds and McGowan 2017) and, consequently, microbiota composition (Turnbaugh 2017).”
BackgroundChang, S.-C., Goh, K. K., & Lu, M. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i10.696 · Cited by 78
Metadata
- Authors
- Reynolds, G. P., & McGowan, O. O.
- Affiliations
- Sheffield Hallam University (GB)
- NHS Lanarkshire (GB)
- Corresponding author
- Reynolds, Gavin P
- ORCID
- Reynolds, Gavin P
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2017-09-11
- Volume
- 31
- Issue
- 11
- Pages
- 1430-1436
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2753967614
- Cited by
- 67
- References
- 77
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 6 · 2023: 7 · 2022: 7 · 2021: 6 · 2020: 13 · 2019: 10 · 2018: 4 · 2017: 1
- FWCI
- 1.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- SHURA (Sheffield Hallam University Research Archive) (Sheffield Hallam University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- antipsychotic-induced weight gain, schizophrenia, metabolic disorders, cardiovascular risk, 5-HT2C receptor, dopamine D2 receptor, histamine H1 receptor, M3 muscarinic receptor, glucose regulation, aripiprazole, pharmacogenetics, drug response variability, predictive genetic testing, personalized medicine
- MeSH terms
- Animals, Humans, Pharmacogenetics, Psychotic Disorders, Risk Factors, Schizophrenia, Antipsychotic Agents, Weight Gain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mechanisms underlying metabolic disturbances associated with psychosis and antipsychotic drug treatment. https://app.cochat.ai/papers/10.1177/0269881117722987
- The paper
- Reynolds, G. P., & McGowan, O. O. (2017). Mechanisms underlying metabolic disturbances associated with psychosis and antipsychotic drug treatment. Journal of Psychopharmacology. https://doi.org/10.1177/0269881117722987
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.